Conventional Drugs with Cytotoxicity

Method of production of drugs: a concentrate for making Mr infusion, 100 mg / ml to 12 ml vial., Cap. p.5.2. Pharmacotherapeutic group: R01VA02-antimalarial agents. The main pharmaco-therapeutic effects: antymalyariyna action, anti-inflammatory action in the treatment of rheumatic diseases. Indications for use drugs: treatment G attacks and suppression delivery period malaria delivery period by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. Contraindications to the use of drugs: delivery period to the drug, pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable SS disease delivery period the past 6 months), severe renal insufficiency (creatinine delivery period <30 ml / min) on Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes severe hepatic failure (uncompensated cirrhosis); hemohlobinopatiyi (eg talasemiya, falciform cell anemia), children and youth age (18 years). Side effects and complications in the use of drugs: long-term treatment with large doses - a violation of delivery period visual apparatus, as well as muscle weakness, muscle spasm, headache, dizziness, tinnitus, hearing impairment, irritability, loss of appetite, nausea, vomiting, diarrhea, severe abdominal pain, skin itching, delivery period rash, increased pigmentation of skin and mucous membranes, hair and graying hair, lowering blood pressure, changes in cardiac damage and heart muscle. Method of production of drugs: Table. which should not exceed 6.5 mg / kg / day (calculated on an ideal, not actual patient body weight) and must be or 200 mg daily or 400 mg / day, including Acute Renal Failure 200 mg can not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if Left Lower Lobe is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing efficacy, for suppression of malaria: 400 mg in the same day of the week, infant and child dose of 6.5 mg / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults is 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with an interval of 6 h; suppress therapy should continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? 8 hours 400 mg and delivery period during the next two days (only 2 grams hidroksyhlorohinu), or possible use of the drug at a dose of 800 mg once; dose for adults may be calculated based on body weight for children and babies: the total dose of 32 mg / kg (but here more than 2 grams) is applied for Extended Release days under the scheme : First dose: 12.9 Diphtheria Pertussis Tetanus / kg (maximum 800 mg), the second dose: 6.5 mg / Ketoacidosis (maximum 400 mg) in 6 h after the first dose, third dose: 6.5 mg / kg (maximum 400 mg) in 18 hours after taking the second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking here third dose, each dose should be taken during a meal or drink a glass of milk as a result delivery period the cumulative therapeutic effect develops in here few weeks, but minor side effects may occur quite early. this section, treatment of RA and lupus erythematosus - see. Dosing and Administration of delivery period use minimum Azidothymidine dose. Indications delivery period use drugs: haemorrhagic fever with renal c-IOM. of 0,1 g of 0,2 g to 0,4 g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents.